2021 Essex County Council election

Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium

Retrieved on:

Wednesday, February 8, 2023

BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLDSymposium taking place February 22-26, 2023, in Orlando, Florida.

Key Points:

BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLDSymposium taking place February 22-26, 2023, in Orlando, Florida.
“The data to be presented at WORLD 2023 represents significant progress toward our mission of ending the devastation of severe genetic diseases though the transformative potential of HSC gene therapy,” said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
Oral presentation details are as follows (all times in EST; * denotes corresponding poster):
Date/Time: Friday, February 24 at 8:00 a.m.
Title: A MLD newborn screening pilot-study for metachromatic leukodystrophy in Germany: Results of the first 12 months
Date/Time: Saturday, February 25 from 4:00-5:00 p.m.
Date/Time: Saturday, February 25 from 4:00-5:00 p.m.

Hyperfine Swoop® Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract Inclusions

Retrieved on:

Monday, February 6, 2023

The annual ISMRM and ISMRT meeting, taking place this year in Toronto June 3–8, highlights current and emerging technological advances in magnetic resonance imaging and medicine worldwide.

Key Points:

The annual ISMRM and ISMRT meeting, taking place this year in Toronto June 3–8, highlights current and emerging technological advances in magnetic resonance imaging and medicine worldwide.
The scope of the cutting-edge research covers a wide range of topics, including phase-sensitive reconstruction, diffusion-tensor imaging, and super-resolution imaging.
Researchers will present the abstract Tensors and Tracts at 64mT as a “Power Pitch,” which highlights the most exciting abstracts of the annual meeting.
With the portable, ultra-low-field Swoop® system, Hyperfine aims to redefine the neuroimaging workflow by bringing brain imaging to the patient’s bedside.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on:

Friday, February 3, 2023

Well, BioCryst Pharmaceuticals, American Academy, RESEARCH, Poster, Caregiver, American Academy of Allergy, Asthma, and Immunology, AAAAI, HAE, Quality of life, CT, Hereditary angioedema, Berotralstat, PARK, 2021 Essex County Council election, Medical imaging, Patient

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

Key Points:

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.
“We continue to build a consistent library of evidence that showcases the value of ORLADEYO through a combination of new analyses from our long-term clinical program and real-world evidence,” said Dr. Ryan Arnold, chief medical officer of BioCryst.
“From new real-world evidence that further demonstrates a meaningful reduction in attack rates experienced by patients who are on ORLADEYO, to additional analyses detailing sustained improvements in patient-reported QoL, the findings that we will present at AAAAI continue to show that our oral, once-daily prophylactic therapy is making a difference for many patients living with HAE.”
The four abstracts that BioCryst will present are:
Disease and Treatment Burden of Hereditary Angioedema (HAE) in Pediatric Patients: Assessment by Caregivers; Poster #417; Sunday, February 26, 9:45-10:45 am CT
Long-term HAE Prophylaxis with Berotralstat Is Well Tolerated and Effective: Analysis for the APeX-S Study; Poster #398; Sunday, February 26, 9:45-10:45 am CT
Berotralstat Improved Quality of Life through 96 Weeks Across Multiple Subgroups of Patients with Hereditary Angioedema; Poster #426; Sunday, February 26, 9:45-10:45 am CT
Real-World Outcomes in Patients with Hereditary Angioedema (HAE) Treated with Berotralstat; Poster #415; Sunday, February 26, 9:45-10:45 am CT

International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event

Retrieved on:

Thursday, February 2, 2023

BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and virtually on March 17–18, 2023, in Boca Raton, Florida.

Key Points:

BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and virtually on March 17–18, 2023, in Boca Raton, Florida.
IMF Patient and Family Seminars gather doctors, patients, and families alike to share stories and connect with those on similar journeys in the myeloma community.
The Boca Raton Patient and Family Seminar will include presentations from internationally esteemed myeloma researchers from all over the world.
Leading up to the event, the IMF will announce additional expert speakers for the upcoming Boca Raton Patient and Family Seminar.

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Retrieved on:

Wednesday, February 1, 2023

Upon execution of a potential agreement at a future time, we would ensure all derivative intellectual property be exclusively owned by Qualigen Therapeutics.

Key Points:

Upon execution of a potential agreement at a future time, we would ensure all derivative intellectual property be exclusively owned by Qualigen Therapeutics.
As a result of these changes, certain executive responsibilities were reassigned by expanding the role of our current President and Chief Strategy Officer, Amy Broidrick, to become President, Chief Strategy and Operating Officer effective as of February 16, 2023.
We are grateful to our many stockholders who have loyally stood by us as we steadfastly execute on our long-range operating plan.
We look forward to providing more updates as they develop, and to communicate with our valued stockholders and stakeholders along the way.

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

Retrieved on:

Tuesday, January 31, 2023

American Thoracic Society, RNA transfection, ATyr Pharma, Sarcoidosis, MOA, Myelocyte, DC, Conference, ATS, Patient, SAN, International Conference on Information Systems Security and Privacy, 2021 Essex County Council election, Pharmaceutical industry

SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the mechanism of action (MOA) and exposure-efficacy analysis for its lead therapeutic candidate, efzofitimod, in an oral symposia presentation and poster session, respectively, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC.

Key Points:

“These abstracts highlight the important data we continue to generate for efzofitimod and our clinical program in pulmonary sarcoidosis, a major form of interstitial lung disease with high unmet medical need,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
Additionally, an exposure-efficacy analysis of efzofitimod provides further confirmatory evidence of clinical proof-of-concept from our previous study.”
Preliminary details of the presentations appear below.
Additional information regarding the presentations will be released closer to the date of the ATS conference.
Title: Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells

Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer

Retrieved on:

Monday, January 30, 2023

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the appointment of Gavin Choy, PharmD as Chief Operating Officer.

Key Points:

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the appointment of Gavin Choy, PharmD as Chief Operating Officer.
“Gavin’s extensive experience facilitating new drug products through the clinical trial process is a welcomed addition to the talented team at Beyond Cancer,” commented Selena Chaisson, Chief Executive Officer of Beyond Cancer.
He most recently served as Chief Clinical Development Officer at GT Biopharma where he authored an orphan drug application submission, co-authored an abbreviated clinical study report, and implemented their quality system.
He also holds a Master of Business Administration focused on Health Care from the University of California, Irvine, Paul Merage School of Business.

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

Retrieved on:

Monday, January 23, 2023

Food, Kidney disease, Kidney, NFK, Lanthanum carbonate, Risk, Chronic kidney disease, Kidney failure, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, LOS, 2021 Essex County Council election, DDI, Therapy, National Kidney Foundation, Pharmaceutical industry

LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023.

Key Points:

LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023.
“With the recently announced results of our successful bioequivalence study of Renazorb compared to Fosrenol®, we expect to file a New Drug Application with the U.S. Food and Drug Administration (FDA) in mid-2023.
These data provide further evidence of the benefits of Renazorb as a powerful phosphate binder and highlight its enhanced product profile, which is expected to improve medication compliance and, thereby, improve outcomes and quality-of-life for chronic kidney disease patients with hyperphosphatemia.”
“We are very encouraged by the UNI-494 data to be presented as it should underscore the prodrug’s potential to be reno-protective and to have low risk of DDI, both of which are important findings for this product candidate as a promising therapeutic for acute kidney disease, a condition for which there are currently no FDA approved therapies,” added Dr. Gupta.
Fosrenol is a registered trademark of Shire International Licensing BV.

ISHLT2023 Meeting Final Program Announced

Retrieved on:

Friday, January 20, 2023

International Society for Heart and Lung Transplantation, Science, International Society, Lung transplantation, Court of general sessions, Heart, 2021 Essex County Council election, Final Program (musical group), Friends, MD, CO, Research, Dentistry

Chicago, USA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The Final Program for the 43rd International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions is now available.

Key Points:

Chicago, USA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The Final Program for the 43rd International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions is now available.
“On behalf of the Program Planning Committee, I’m happy to welcome the ISHLT community to Denver in April 2023,” says Howard Eisen, MD, ISHLT 2023 Scientific Program Chair.
The Final Program now available on ISHLT.org features a variety of new innovative symposia formats, including pecha kucha and debate-style sessions."
I’d like to express my sincere admiration and gratitude to the entire Annual Meeting Program Planning Committee for their time and effort to create this engaging and diverse Scientific Program.”

ISET celebrates 35th anniversary meeting with nearly 1,000 registrants, record-breaking number of research submissions, sold out Exhibit Hall

Retrieved on:

Thursday, January 19, 2023

MALVERN, Pa., Jan. 19, 2023 /PRNewswire-PRWeb/ -- For its 35th annual gathering, HMP Global's International Symposium on Endovascular Therapy (ISET) received a record-breaking amount of research submissions, welcomed nearly 1,000 registrants from around the globe, and hosted more than 40 companies in its sold-out Exhibit Hall, solidifying its position as the premier arena for pioneering and practical endovascular education.

Key Points:

"From the group that pioneered live case education, ISET has grown tremendously since the first meeting 35 years ago," Katzen said.
"Now as the leading meeting in endovascular therapy, ISET brings together a multidisciplinary faculty and audience to discuss groundbreaking techniques, implement change, and improve patient care.
All abstracts underwent blind peer review for quality of research, educational or scientific content, logical presentation, and impact on healthcare.
Cutting-edge research e-posters were displayed on multimedia screens in the poster area of the Exhibit Hall at ISET, and late-breaking data was presented at the first major endovascular meeting in 2023.